Document:

Form of Stock Option Agreement

 Exhibit 4.2 
 NEOGENOMICS, INC. 
 EQUITY INCENTIVE PLAN 

STOCK OPTION AGREEMENT 
 Pursuant to this Stock Option Agreement (“Agreement”), NeoGenomics, Inc. (the “Company”) has granted you an option (“Stock Option”) under its Amended and Restated Equity
Incentive Plan, dated March 3, 2009 (the “Plan”) to purchase the number of shares of the Company’s Common Stock at the exercise price and in accordance with the vesting schedule indicated herein. Defined terms not explicitly
defined in this Stock Option Agreement but defined in the Plan shall have the same definitions as in the Plan. 
 The details of
your Stock Option are as follows: 
  

					
	Optionee (“you”):	  		  	Maher Albitar, M.D.
			
	Address of Optionee:	  		  	27165 Kiavo Dr.
		  		  	Valley Center, CA 92082
			
	Date of Grant:	  		  	January 9, 2012
		
	Vesting Commencement Date:	  	January 9, 2012
		
	Number of Shares Subject to the Stock Option:	  	250,000
			
	Exercise Price:	  	Per Share $ 1.43	  	Total $ 357,500
			
	Type of Grant:	  	 ̈ Incentive Stock Option	  	XXX  Non-Qualified Stock Option

					
		
	Vesting Schedule:	  	Your Stock Option shall vest based on the following schedule:
			
		  	 62,500 on January 9, 2013

62,500 on January 9, 2014
 62,500 on January 9, 2015
 62,500 on January 9, 2016
	  	

 Authorization for Grant: This Stock Option was granted to you pursuant to that certain letter
agreement between you and the Company dated January 6, 2012 and accepted by you on January 6, 2012 that created an exclusive medical services contractor relationship between the Company and you (the “Offer Letter”) and that
certain Medical Services Agreement, dated January 6, 2012 (the “Contractor Agreement”) executed by you and the Company. This grant was authorized by the Board of Directors of the Company at a telephonic Board Meeting held on
January 6, 2012. 
 Expiration Date: Unless sooner terminated in accordance with this Agreement or the terms of the
Plan, the Stock Option will terminate on the fifth anniversary of the Date of Grant. 

  
 - 1 -

 Section 1. Grant of Stock Option. 

1.1 Type of Stock Option. The type of Stock Option that you have been awarded is referenced above. 

1.2 This Section Intentionally Left Blank. 
 1.3 Number of Shares and Exercise Price. The number of shares of Common Stock subject to your Stock Option and the exercise price per share referenced above may be adjusted from time to time
for capitalization adjustments, as provided in Section 22 of the Plan. 
 Section 2. Vesting. Subject to
the limitations, if any, provided in the Plan or contained herein, your Stock Option will vest as provided above. 

Section 3. Exercise of Stock Options. Except as otherwise provided herein, and subject to the provisions of the Plan
(including restrictions on the transferability of the Stock Option and special provisions relating to exercise or termination of the Stock Option following your termination, death or Disability, certain changes in capitalization of the Company or a
merger or asset sale), the Stock Option granted pursuant to this Agreement shall be subject to exercise as follows: 
 (a)
You may exercise the vested portion of your Stock Option during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Committee, or to such other person as the Committee may
designate, during regular business hours, together with such additional documents as the Company may then require. 
 (b)
By exercising your Stock Option, you agree that, as a condition to any exercise of a Stock Option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the
Company arising by reason of (1) the exercise of your Stock Option, (2) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (3) the disposition of shares of
Common Stock acquired upon such exercise. 
 (c) If your Stock Option is an Incentive Stock Option, by exercising your
Stock Option, you agree to notify the Company in writing within 15 days after the date of any disposition of any of the shares of Common Stock issued upon exercise of your Stock Option that occurs within two years after the Date of Grant or within
one year after such shares of Common Stock are issued upon exercise of your Stock Option. 
 (d) By exercising your Stock
Option, you agree that the Company (or a representative of the underwriter(s)) may, in connection with the first underwritten registration of the offering of any securities of the Company under the Act, require that you not sell, dispose of, assign,
encumber, transfer, make any short sale of, grant any Stock Option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any shares of Common Stock or other securities of the Company held by
you, for a period of time specified by the underwriter(s) (not to exceed 180 days) following the effective date of the registration 

  
 - 2 -

 
statement of the Company filed under the Act. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are
consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such
period. 
 Section 4. Method of Payment. Payment of the exercise price is due in full upon exercise of all or any part of the
Stock Option. You may elect to make payment by one or a combination of the following methods: 
 (a) Cash, check or wire
transfer; 
 (b) In the Committee’s sole discretion at the time your Stock Option is exercised and provided that at
the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board which, prior to the issuance of Common
Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds attributable to such Common Stock; or 

(c) Provided that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal,
by delivery of already-owned shares of Common Stock either that you have held for the period required to avoid a charge to the Company’s reported earnings (generally six months) or that you did not acquire directly or indirectly from the
Company, that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these purposes, in the sole discretion of the Committee at
the time you exercise your Stock Option, shall include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Committee. Notwithstanding the foregoing, you may not exercise your Stock Option
by tender to the Company of Common Stock to the extent such tender would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 

Section 5. Whole Shares. You may exercise your Stock Option only for whole shares of Common Stock. 

Section 6. Term of Stock Option. 
 6.1 Commencement. The term of your Stock Option commences on the Date of Grant. 
 6.2 Expiration. Except as otherwise provided in Section 35 of the Plan in the event of a merger or sale under certain circumstances, the term of your Stock Option expires upon the
earliest of the following: 
 (a) immediately upon the termination of your service with the Company or any Subsidiary,
whether as an employee, officer, director, adviser or consultant, for “Cause” (as such term is defined below) or upon the breach by you of any of the covenants set forth in Section 9 below, except as otherwise provided in
Section 9.3 below; 

  
 - 3 -

 (b) three months after the termination of your services with the Company for any
reason other than death or Disability, provided that if during any part of such three month period your Stock Option is not exercisable solely because of the condition set forth in Section 7 below relating to “Securities Law
Compliance”, your Stock Option shall not expire until the earlier of the Expiration Date or until it shall have been exercisable for an aggregate period of three months after the termination of your service with the Company; 

(c) 12 months after the termination of your service with the Company due to death or Disability; 

(d) the Expiration Date; or 
 (e) the fifth anniversary of the Date of Grant. 
 6.3 Cause.
For purposes of this Agreement, the termination of your services with the Company for “Cause” shall mean termination due to any of the reasons listed in Section 6 (b) of the Contractor Agreement. 

6.4 Disability. For purposes of this Agreement, “Disability” shall mean any mental or physical illness,
condition, disability or incapacity which prevents you from reasonably discharging your duties and responsibilities to the Company for a period of forty five (45) days in any ninety day period. In the event that any disagreement or dispute
shall arise between the Company and you as to whether you suffer from any Disability, then, in such event, you shall submit to the physical or mental examination of a physician licensed under the laws of the state in which you reside, who is
mutually agreeable to you and the Company, and such physician shall determine whether you suffer from any Disability. In the absence of fraud or bad faith, the determination of such physician shall be final and binding upon the Company and you.

 6.5 Incentive Stock Option Employee Rule. If your Stock Option is an Incentive Stock Option, note that to
obtain the federal income tax advantages associated with an “Incentive Stock Option,” the Code requires that at all times beginning on the Date of Grant of your Stock Option and ending on the day three months before the date of your Stock
Option’s exercise, you must be an employee of the Company or a Subsidiary or Parent Company, except in the event of your death or Disability. The Company has provided for extended exercisability of your Stock Option under certain circumstances
for your benefit but cannot guarantee that your Stock Option will necessarily be treated as an “Incentive Stock Option” if you continue to provide services to the Company or a Subsidiary or Parent Company as a consultant, adviser or
director after your employment terminates or if you otherwise exercise your Stock Option more than three months after the date your employment terminates. 

  
 - 4 -

 Section 7. Securities Law Requirements. Notwithstanding anything to the
contrary contained herein, you may not exercise your Stock Option unless the shares of Common Stock issuable upon such exercise are then registered under the Act or, if such shares of Common Stock are not then so registered, the Company has
determined that such exercise and issuance would be exempt from the registration requirements of the Act. The Company may request a legal opinion of your counsel, reasonably satisfactory to the Company, with respect to such exemption. The exercise
of your Stock Option must also comply with other applicable laws and regulations governing your Stock Option, and you may not exercise your Stock Option if the Company determines that such exercise would not be in material compliance with such laws
and regulations or would result in liability under Section 16 of the Securities Exchange Act of 1934, as amended. 

Section 8. Change of Control. Notwithstanding the provisions of Section 2, in the event that a Change of Control
shall occur after the Date of Grant, all unvested portions of your Stock Option shall vest in full. For purposes of this Section 8, “Change of Control” means the occurrence of any of the following events: (i) any
“person” or “group” (as defined in Section 13(d) and 14(d) of the Exchange Act) together with their affiliates become the ultimate “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act) of voting stock
of the Company representing more than 50% of the voting power of the total voting stock of the Company; (ii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation or entity regardless of
which entity is the survivor, other than a merger or a consolidation which would result in the voting stock of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or being converted into voting
securities of the surviving entity or the parent thereof) at least 50% of the combined voting power of the voting securities of the Company or such surviving entity or the parent thereof, outstanding immediately after such merger or consolidation;
or (iii) the stockholders of the Company approve a plan of complete liquidation or winding up of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets. 

Section 9. Confidentiality and Non-Compete. In connection with and in consideration for the grant of this Stock Option
to you, the Company and you have executed a Confidentiality, Title to Work Product and Non-Solicitation Agreement, dated January 6, 2012 (the “Work Product Agreement”) and a Confidentiality and Non-Compete Agreement, dated
January 6, 2012 (the “Non-Compete Agreement”, and together with the Work Product Agreement, the “Ancillary Agreements”), which are incorporated into this Agreement by reference, and you hereby acknowledge your obligations
thereunder. You further agree that if you violate any provision of the Ancillary Agreements, you shall immediately forfeit any rights and benefits under your Stock Option, this Agreement and the Plan; provided, however, that any inadvertent
violations of the provisions set forth in the Ancillary Agreements that have not had or are not expected to have a material impact on the Company shall not result in the forfeiture of your rights and benefits under your Stock Option, so long as you
notify the Company upon becoming aware of such inadvertent violations and agree to rectify and/or cease such activities immediately. Nothing in this Section 9 or the Ancillary Agreements will be deemed to limit, in any way, the remedies at law
or in equity of the Company for a breach by you of any of the provisions of this Section 9 or the Ancillary Agreements. 

  
 - 5 -

 Section 10. No Right to Continue Employment or Service. Nothing in this
Agreement, the Plan, or your Notice of Exercise shall confer upon you any right to continue to serve the Company or any Subsidiary in the capacity in effect at the time the Stock Option was granted or shall affect the right of the Company or any
Subsidiary to terminate (i) your employment, if you are an employee, with or without notice and with or without cause, (ii) your service as a consultant or adviser, if you are a consultant or adviser, pursuant to the terms of your
agreement with the Company or any Subsidiary or (iii) your service as a director, if you are a director, pursuant to the Bylaws of the Company or any Subsidiary and any applicable provisions of the corporate law of the state in which the
Company or any Subsidiary is incorporated, as the case may be. 
 Section 11. Withholding of Taxes.

 (a) At the time you exercise your Stock Option, in whole or in part, or at any time thereafter as requested by the
Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed under Regulation T
as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or a Subsidiary, if any, which arise in connection
with your Stock Option. 
 (b) Upon your request and subject to approval by the Company, in its sole discretion, and
compliance with any applicable conditions or restrictions of law, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your Stock Option a number of whole shares of Common Stock having a
Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law. If the date of determination of any tax withholding obligation is deferred to a date later than the
date of exercise of your Stock Option, share withholding pursuant to the preceding sentence shall not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common
Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your Stock Option. Notwithstanding the filing of such
election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your Stock Option that are otherwise issuable to you upon such exercise. Any adverse consequences to you
arising in connection with such share withholding procedure shall be your sole responsibility. 
 (c) You may not
exercise your Stock Option unless the tax withholding obligations of the Company and/or any Subsidiary are satisfied. Accordingly, you may not be able to exercise your Stock Option when desired even though your Stock Option is vested, and the
Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein or under the Plan. 

  
 - 6 -

 Section 12. Non-Assignability. Your Stock Option is not transferable,
except by will or by the laws of descent and distribution, and is exercisable during your life only by you. Notwithstanding the foregoing, by delivering written notice to the Company, in a form satisfactory to the Company, you may designate a third
party who, in the event of your death, shall thereafter be entitled to exercise your Stock Option. 
 Further, with the approval
of the Committee, you may transfer your Non-Qualified Stock Option for no consideration to or for the benefit of your Immediate Family (including, without limitation, to a trust for the benefit of your Immediate Family or to a partnership or limited
liability company for one or more members of your Immediate Family), subject to such limits as the Committee may establish, and the transferee shall remain subject to all the terms and conditions applicable to your Non-Qualified Stock Option prior
to such transfer. The term “Immediate Family” shall mean your spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers and grandchildren (and, for this purpose, shall also include you). 

At your request and subject to the approval of the Committee, Common Stock purchased upon exercise of your Non-Qualified Stock Option may
be issued or transferred into your name and the name of your spouse jointly with rights of survivorship. 
 Section 13.
Notice. For purposes of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given (a) one business day following confirmed facsimile
transmission, (b) three business days after being delivered or mailed by United States registered mail, return receipt requested, postage prepaid, or (c) one business day after being sent via overnight delivery service, as follows:

 If to the Company: 
 NeoGenomics, Inc. 
 12701 Commonwealth Drive, Suite 5 

Fort Myers, FL 33913 
 Attn: Chief Financial Officer or Director of Finance 
 Facsimile No.:
(239) 768-0711 
 and, if to you, to the address shown on this Agreement, or to such other address as either party may have furnished to
the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt. 

Section 14. Governing Plan Document. Your Stock Option granted pursuant to this Agreement is subject to the terms and
conditions set forth in the Plan, a copy of which is attached to this Agreement. All the terms and conditions of the Plan, as may be amended from time to time, and any rules, guidelines and procedures which may from time to time be promulgated and
adopted pursuant to the Plan, are hereby incorporated into this Agreement, without regard to whether such terms and conditions (including, for example, provisions relating to certain changes in capitalization of the Company) are not otherwise set
forth in this Agreement. In the event of any conflict between the provisions of this Agreement and of the Plan, the provisions of the Plan shall govern. 

  
 - 7 -

 Section 15. Governing Law. The Plan shall be construed in accordance with
the laws of the State of Nevada. 
 [Signatures Appear on the Following Page.] 

  
 - 8 -

 By signing below, the undersigned Optionee acknowledges receipt of, and understands and
agrees to, this Stock Option Agreement and the Plan. Optionee further acknowledges that as of the Date of Grant, the Stock Option Agreement and the Plan set forth the entire understanding between Optionee and the Company regarding the Stock Option
and the acquisition of Common Stock of the Company pursuant to the exercise thereof and supersede all prior oral and written agreements on that subject, with the exception of Stock Options previously granted and delivered to Optionee under the Plan.

  

									
	NeoGenomics, Inc.	 		 	Optionee:
					
	By:	 	 /s/ Steven C. Jones
	 		 		 	 /s/ Maher Albitar, M.D.

	Name:	 	      Steven C. Jones
	 		 	Name:	 	 Maher Albitar, M.D.

	Title:	 	      Executive Vice President, Finance
	 		 		 	
					
	Date:	 	 1/6/2012
	 		 	Date:	 	 1/6/2012

  
 - 9 -Medical Services Agreement

 Exhibit 10.1 
 Medical Services Agreement 
 This Medical Services Agreement (“Agreement”) is made and
entered into on January 6th by and between ALBITAR ONCOLOGY CONSULTING, LLC, a Delaware limited liability corporation (“Medical Group”), with its mailing address at 27165 Kiavo Drive, Valley Center, CA 92082 and NEOGENOMICS
LABORATORIES, INC., a Florida Corporation (“NeoGenomics”). 
 RECITALS 

WHEREAS, NeoGenomics operates a clinical laboratory, licensed in accordance with the California Business and Professions Code, Sections 1200
et. seq. and the regulations adopted pursuant thereto, and the Clinical laboratory Improvement Amendments of 1988 (42 U.S.C. §263a) and the regulations adopted pursuant thereto (“CLIA”), located at 6 Morgan, Suite 150, Irvine,
California 92618 (the “Laboratory”), in which it performs the technical component of certain high-complexity pathology tests (“Diagnostic Tests”), and 
 WHEREAS, NeoGenomics requires the professional services of Medical Group and desires to engage Medical Group to render and perform the professional component of the Diagnostic Tests through the
services of one or more physicians who are licensed and legally authorized to render such professional services in the State of California, and 

WHEREAS, Medical Group employs MAHER ALBITAR, M.D., who is licensed and authorized to practice medicine in the State of California
(“Physician”) and is trained, experienced and board-certified in the field of pathology, and Medical Group is willing to provide the professional expertise and experience through its Physician in those areas required or desired by
NeoGenomics; and 
 WHEREAS, Medical Group is solely owned by the Physician and is expected to be solely owned by the Physician during
the term of this Agreement; and 
 WHEREAS, NeoGenomics desires to contract with Medical Group for the rendition and performance of the
professional component of the Diagnostic Tests, the management of certain new product development and clinical trial activities, and the provision of Medical Administrative Services, as more fully described in this Agreement, and Medical Group
agrees to render and perform such services on an independent contractor basis to NeoGenomics, on the terms and conditions set forth in this Agreement; and 
 WHEREAS, Medical Group desires to engage the services of NeoGenomics to provide management services in the manner hereinafter stated, and NeoGenomics agrees to provide such management services, on
the terms and conditions stated in this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, which are hereby
incorporated into this Agreement as an integral part hereof, and the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, NeoGenomics and
Medical Group/Physician, intending to be legally bound, hereby agree as follows: 
 1. PROFESSIONAL COMPONENT AND MEDICAL ADMINISTRATIVE
SERVICES: NeoGenomics shall engage Medical Group to provide and Medical Group shall employ Physician on a full-time basis to (a) perform the professional interpretation of the Diagnostic Tests performed by Laboratory (the “Professional
Component”), (b) provide new product development and clinical trials management services, and (c) to provide medical administrative services. Such new product development and clinical trials management services will include, but not
be limited to, providing general oversight and management direction to NeoGenomics with respect to launching new laboratory tests and conducting clinical trials (“Management Services”). Those medical administrative services will include,
but not be limited to, providing liaison services with health care providers and ordering physicians, reviewing and establishing protocols for testing, establishing clinical parameters for procedures, evaluating and making recommendations regarding
new diagnostic procedures, providing in-service education to the Laboratory staff, providing community education to medical service providers, and such other administrative 

  
 Page 1 of 8

 
functions as NeoGenomics may reasonably request (“Medical Administrative Services”, and together with the Professional Component services, and the Management Services, the
“Services”). Unless otherwise agreed upon between the parties in writing, Medical Group and its Physician shall perform all functions related to the Services at the Laboratory. Medical Group and Physician further agree that they will not
provide services under this Agreement at any location other than the Laboratory unless such location has obtained the appropriate California licensures and has been CLIA certified and that Physician shall provide the Services on a full-time basis on
behalf of NeoGenomics. Notwithstanding the foregoing, the term “full-time” shall not exclude the Physician from continuing his work as a Director on the Board of Directors and a Consultant to Health Discovery Corporation as long as this
work is not cancer or hematology-related, or such other work to third parties as may be mutually agreed upon. 
 2. MANAGEMENT SERVICES AND
DUTIES: Medical Group hereby engages NeoGenomics to perform administrative, non-physician services for the daily support of the business operations of Medical Group’s practice (the “Practice”). These services shall include,
without limitation: 
  

	 	(a)	transcribing reports, transmitting reports to referring physicians, all other technical support necessary to provide professional pathology services, non-medical staff
support, quality control, marketing, advertising, office space, furniture, fixtures, equipment, facility and equipment maintenance, utilities, maintenance, janitorial services, supplies, managed care contract administration (including, without
limitation, revenue recovery and member eligibility determination), accounting, bookkeeping, budgeting, record storage, preparation of financial reports, billing, accounts payable, accounts receivable, management information systems, facilities
management, liability insurance, workers compensation insurance, and property and casualty insurance in connection with the services provided by Medical Group to NeoGenomics pursuant to this Agreement. 

 

	 	(b)	During the term of this Agreement, NeoGenomics shall use its skills and efforts to the performance of, and to perform diligently on a timely basis, its duties.
NeoGenomics shall comply with all applicable laws, regulations and administrative procedures of federal and state government agencies and their agent in the billing and collection of services rendered on behalf of NeoGenomics by Medical Group.
NeoGenomics shall defend and indemnify Medical Group from any claim due or alleged to be due to false or fraudulent billing performed by NeoGenomics. Medical Group and its Physicians shall retain full control over, and NeoGenomics shall exert no
control over, the exercise of professional judgment and care in all tasks performed as a licensed physician and the administrative functions pertaining thereto. 

 3. COMPENSATION 
  

	 	(a)	Payment for Services: 

  

	 	(i)	As consideration for the Services provided by the Physician and Medical Group hereunder, NeoGenomics shall pay to Medical Group a minimum annual amount (the “Base
Compensation”) equal to $425,000; in equal increments of $16,346, payable on a bi-weekly basis. 

  

	 	(ii)	 NeoGenomics agrees that included within this Base Compensation is a provision for up to five (5) weeks of paid time off per year for Physician,
which shall accrue and be earned on a pro rata basis through each year. Such period of paid time off shall cover all normal working days where Physician is not available to provide Services to NeoGenomics as a result of vacation, continuing
education classes or otherwise. Medical Group and Physician agree that that in the event that Physician provides Services for less than 47 weeks per year, such Base Compensation shall be prorated accordingly. Notwithstanding the forgoing,
NeoGenomics agrees that Physician will not be expected to provide Services on any legal holidays formally recognized by NeoGenomics. Physician and Medical Group agree that they will notify NeoGenomics in writing of any time that Physician will be
unavailable to provide services during normal working hours and, to the extent possible, at least four weeks in advance of any period in which 

  
 Page 2 of 8

	 	
Physician will be unavailable to provide Services for longer than one day. Physician and Medical Group further agree that Physician will not take vacation or otherwise be unavailable to
provide services for a period of longer than two weeks at any given time while this Agreement is in effect without the prior written approval of NeoGenomics and that any unused paid time-off cannot be carried forward past December 31st of any given calendar year. 

 

	 	(iii)	As additional consideration for the Professional Component and the Medical Administrative Services, NeoGenomics will pay the Medical Group an amount, determined in the
Company’s discretion, up to 25% of the Base Compensation paid by the Company during any of its fiscal years within sixty (60) days of the end of any such fiscal year, if Medical Group meets certain performance thresholds established for it
by the Company (the “Incentive Compensation”) and this Agreement has not otherwise been terminated prior to the time of each such payment. 

  

	 	(iv)	The Base Compensation and the Incentive Compensation shall be paid to the Medical Group without regard to the actual fees collected by NeoGenomics that may represent
the reimbursement for the Professional Component of the Diagnostic Tests performed. If such fees actually collected are not sufficient to cover the Base Compensation and the Professional Compensation, then NeoGenomics shall pay such difference from
its own resources, and such amounts shall not be subject to reimbursement, recoupment or offset from previously or subsequently collected Base Compensations and Professional Compensation. 

 

	 	(v)	NeoGenomics will also reimburse Medical Group for up to $5,000 annually for expenses associated with Physician’s continuing medical education (“CME”)
credits. 

  

	 	(vi)	NeoGenomics will also pay all states licensing fees for Physician. 

  

	 	(vii)	Physician will be entitled to participate in all medical benefits that NeoGenomics offers to its independent contractors (reported on IRS Form 1099) in accordance with
the Company’s policy for such benefits at any given time. In this regard, NeoGenomics will pay that portion of such benefits as it would normally pay for full-time employees of NeoGenomics. NeoGenomics reserves the right to modify its benefit
programs at any time in its sole discretion. 

  

	 	(viii)	This Agreement has been negotiated on the basis of the Medical Group employing only the Physician. If Medical Group hires or retains additional Physician(s) during the
term of this Agreement, then this Agreement shall be renegotiated to account for the effect of that change in the status of the Practice. 

  

	 	(b)	NeoGenomics will bill for the technical component and the professional component of all Diagnostic Tests on a global basis, and all monies received by NeoGenomics for
the Diagnostic Tests that is in excess of the Base Compensation and Incentive Compensation will be retained by NeoGenomics as compensation for the Management Services provided in Section 2(a) (the “Management Fee”). Medical Group and
Physician shall do such things and execute such documents as necessary to enable NeoGenomics to bill and collect for the professional services rendered by Physician pursuant to this Agreement. 

 

	 	(c)	Management Fee after Termination. 

  

	 	(i)	 Upon any termination of this Agreement, NeoGenomics shall continue to bill and collect for all Diagnostic Tests rendered to the date of termination.
NeoGenomics will pay to Medical Group any sums due for Base Compensation and Incentive Compensation due with respect to services rendered by Medical Group through the date of termination. NeoGenomics shall be entitled to retain all additional sums
as post-termination 

  
 Page 3 of 8

	 	
Management Fee. Medical Group shall have no right, title or interest to accounts receivable, proceeds from accounts receivable or other income from any source derived in whole or in part from
services rendered by Medical Group pursuant to this Agreement. 

  

	 	(ii)	If NeoGenomics terminates this Agreement without cause (as hereinafter defined) and without the required 90-days’ written notice, then Medical Group shall be
entitled to be paid the Base Compensation during the 90 day notification period. NeoGenomics shall be entitled to the Management Fee during such period. The Base Compensation and Management Fee will be adjusted ratably depending upon when the
termination occurs during a calendar month. 

 4. RELATIONSHIP OF THE PARTIES: NeoGenomics, on the one hand, and Medical
Group and its Physician, on the other hand, shall act at all times under this Agreement as independent contractors. Nothing in this Agreement shall be construed or be deemed to create a relationship of employer and employee or principal and agent or
any relationship other than that of independent parties contracting with each other solely for the purpose of carrying out the purposes expressed in this Agreement. The Medical Group and Physicians shall exercise at all times independent medical
judgment with regard to the professional interpretation and diagnosis of Diagnostic Tests and the performance of Management Services and the Medical Administrative Services. NeoGenomics shall provide administrative and technical support services to
Medical Group pursuant to the terms of this Agreement and as required by the laws and regulations governing licensed and CLIA-certified clinical laboratories. Medical Group and Physicians shall be solely responsible for determining the manner in
which professional medical services are provided and shall ensure that such services are rendered in accordance with the applicable professional standard of care. Medical Group and Physicians shall at all times be governed and abide by all
applicable clinical licensure, certification, and accreditation laws, regulations, and standards, and the policies and procedures of NeoGenomics adopted to comply with such standards. The relationship of the parties is and shall remain that of
independent parties to a contractual relationship as specified in this Agreement. Each party shall be and remain responsible for all hiring and firing decisions relating to its personnel and for all costs associated with its personnel, including but
not limited to salaries, wages, other compensation, taxes, tax withholding and fringe benefits (if any). In the event the Internal Revenue Service or other government agency should challenge the independent contractor status of the parties, the
parties agree that each party shall have the right to participate in any discussions or negotiations associated therewith. 
 5. NO
CONNECTION TO REFERRALS: The Parties agree and acknowledge that the services to be rendered by the Parties as contemplated by this Agreement shall constitute valuable and necessary services for the operation of NeoGenomic’s clinical
laboratory, and that the amounts payable under Section 3 of this Agreement represent the fair market value of the items and services to be rendered by each Party. The Parties further acknowledge that it is their intention that compensation
payable under this Agreement shall be for actual services rendered and shall not represent, and is not intended to represent remuneration, direct or indirect, in consideration for the referral of patients or business generated between the Parties.

 6. TERM AND TERMINATION 
  

	 	(a)	The term of this Agreement shall commence on January 9, 2012 or such other date as shall be mutually agreed upon between the parties (the “Start Date”),
and shall continue until terminated as hereinafter provided. 

  

	 	(b)	Termination for Cause: 

  

	 	(i)	 NeoGenomics may terminate this Agreement at any time for “Cause” (as hereinafter defined), effective immediately upon written notice to
Medical Group. As used herein, the term “Cause” shall mean: (A) commission of a material breach of this Agreement, which breach is curable, in the judgment of NeoGenomics, and continues 30 days after receipt of notice which states
with particularity the nature of the breach; (B) Medical Group or any Physician is charged with a felony or misdemeanor involving moral turpitude; Medical Group or any Physician commits an act or omission that could subject Medical Group,
Physician or NeoGenomics to administrative sanctions, civil or criminal 

  
 Page 4 of 8

	 	
penalties, fines; or assessments (C) termination, restriction, suspension, exclusion or debarment of Medical Group’s or Physician’s participation in the Medicare, Medi-Cal,
Medicaid, or any other private, state or federal health benefit program; (D) Medical Group or any Physician is charged with a violation of any law pertaining to the performance or rendition of health care goods or services, health care fraud or
abuse, or insurance fraud; or (E) revocation, restriction, suspension or other loss of Physician’s license to practice medicine in any jurisdiction. 

 

	 	(ii)	Medical Group also may terminate this Agreement at any time for “Cause” (as hereinafter defined), effective immediately upon written notice to NeoGenomics. As
used herein, the term “Cause” shall mean a material breach of this Agreement by NeoGenomics which breach continues after 30 days notice and opportunity to cure. 

 

	 	(c)	Termination Without Cause: NeoGenomics or Medical Group may terminate this Agreement without cause, and for any reason or no reason, at any time after giving written
notice of its intention to terminate to the other Party at least ninety (90) days prior to the intended date of termination; provided, however, that NeoGenomics, in its discretion, may make such termination effective immediately or on some date
prior to the expiration of such 90-day notice period, in which event NeoGenomics will pay Medical Group during such 90-day period, or the remainder of such 90-day period, as provided in Section 3(c)(ii) above. 

 

	 	(d)	Change in Law: In the event there is a change or clarification in law, regulation, or policy by a court or governmental agency with regulatory jurisdiction over the
Parties such that any of the terms or provisions of this Agreement could be deemed to be in violation or contravention of applicable law or regulations, or either Party’s right to compensation for its services will be affected materially and
adversely by such changes or clarifications, the Parties agree to take such actions as may be necessary to modify this Agreement and to do such other things as they deem prudent or necessary to bring the affected provisions or terms into compliance
while maintaining the Parties in substantially the same economic position. If the Parties are unable to mutually agree to amend the affected provisions of this Agreement after good faith negotiations, either Party may terminate the Agreement by
providing not less than thirty (30) days advance written notice to the other, it being the express intent of the Parties that this Agreement comply at all times with applicable federal and California laws and regulations. The negotiation period
shall be shortened as necessary to prevent either Party from operating in violation of applicable law. 

 7. PROPRIETARY
CONFIDENTIAL INFORMATION AND TRADE SECRETS: The agreements between the parties with respect to Confidential Information and Trade Secrets are set forth in that certain Confidentiality, Title to Work Product and Non-Solicitation Agreement between
the Physician and NeoGenomics, which is made a part hereof. 
 8. ASSIGNMENT: This Agreement shall not be assignable, in whole or in
part, by either party without the written consent of the other party, except that: 
  

	 	(a)	NeoGenomics, with prior notice to but without the consent of Medical Group, may assign its rights and delegate its obligations under this Agreement to an affiliate; or
to any unaffiliated corporation, firm or other business entity (i) with or into which NeoGenomics may merge or consolidate; or (ii) to which NeoGenomics may sell or transfer all or substantially all of its assets. After any such assignment
by NeoGenomics, NeoGenomics shall be discharged from all further obligations hereunder and such assignee shall thereafter be deemed to be “NeoGenomics” for the purposes of all provisions of this Agreement. 

 

	 	(b)	 Medical Group, with prior notice to NeoGenomics, may assign its rights under this Agreement to an entity created by or affiliated with the Physician.
Upon receipt of such notice, NeoGenomics shall advise Medical Group whether it consents to the assignment, which consent shall not be unreasonably withheld. As a condition to the assignment, assignee shall agree to be bound by the terms of this
Agreement, Medical Group shall then be discharged from all further obligations 

  
 Page 5 of 8

	 	
hereunder, and such assignee shall thereafter be deemed to be “Medical Group” for the purposes of all provisions of this Agreement. This Agreement secures the professional medical
services of Medical Group and Physician based upon the professional training, experience and qualifications of Physician as required by NeoGenomics. Accordingly, Medical Group and Physician shall not delegate any duties, responsibilities or
obligations without the advance written consent of NeoGenomics. 

 9. SURVIVAL AND REMEDIES: Medical Group acknowledges and
agrees that Medical Group’s covenants in this Agreement are reasonable and necessary in order to protect the legitimate interests of NeoGenomics, and that any violation thereof by Medical Group would result in irreparable injuries to
NeoGenomics. Therefore, Medical Group acknowledges and agrees that, in the event of a violation by Medical Group of any of those covenants, NeoGenomics shall be entitled to obtain, from any court of competent jurisdiction, temporary, preliminary and
permanent injunctive relief to prevent a threatened breach or to obtain a halt to an actual breach by Medical Group of any of Medical Group’s covenants contained in this Agreement, in addition to any other rights or remedies to which
NeoGenomics may be entitled at law or in equity by reason of any such breach or threatened breach of this Agreement 
 10. ACCESS TO
RECORDS: The Parties agree to comply with the federal privacy and security laws and regulations enacted pursuant to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). Accordingly, Physician agrees to execute a
Business Associate Agreement contemporaneously with the execution of this Agreement or upon request. Each Party shall document all services rendered in the clinical laboratory records of NeoGenomics during the term hereof in accordance with the
policies and procedures of NeoGenomics. Medical Group shall ensure that each Physician shall prepare and submit such interpretive reports, forms, and documents as reasonably requested by NeoGenomics to document the services rendered pursuant to this
Agreement. Medical Group and Physicians may retain copies of all interpretive reports prepared by Physicians in connection with the Diagnostic Tests. NeoGenomics shall maintain and retain the interpretive reports, as required by Section 1220 of
the California Business and Professions Code and 45 C.F.R. §164.530(j)(2) of HIPAA. Medical Group and each Physician shall have access to and may copy, at its own expense, interpretive reports rendered by such Physician at all times throughout
the term of this Agreement and for the applicable retention period thereafter. The Parties shall comply with all laws and regulations relating to the confidentiality and security of clinical laboratory records. Unless required by service of process,
Medical Group and Physician shall not provide access to or copies of records to any person other than on behalf of and at the request of NeoGenomics. Medical Group and Physician shall promptly advise NeoGenomics upon receipt of any request for
records. 
 Notwithstanding any other provision of this Agreement, in the event the access to records provisions of 42 U.S.C.
§1395x(V)(I) are applicable to this Agreement, until the expiration of four (4) years after the termination of this Agreement, each party shall make available, upon written request to the Secretary of the United States Department of Health
and Human Services, or upon request to the Controller General of the United States General Accounting Office, or any of his or her duly authorized representatives, a copy of this Agreement and such books, documents, or records as are necessary to
certify the nature and extent of the costs of the services provided by each party under this Agreement. In connection with the foregoing, (a) the parties acknowledge and agree that any privileges for documents or information under applicable
attorney-client, accountant-client, or other legal privilege, if any, are not waived by this Section 10, or by any other provision of this Agreement; (b) subject to the other provisions of this Agreement regarding confidentiality, any
party may examine the records of the other party and make copies of those records at the expense of the party seeking the copies (the records are to be available during normal business hours at the principal place of business of the party owning the
records); and (c) the provisions of this Section 10 shall survive the termination of this Agreement. 
 11.
SEVERABILITY: If any provision of this Agreement is held to be invalid, illegal or unenforceable, then that provision shall be reformed to the maximum extent permitted to preserve the parties’ original intent as agreed by the parties;
failing which, such provision shall be severed from this Agreement with the balance of the Agreement continuing in full force and effect. Such occurrence shall not have the effect of rendering the provision in question invalid in any other
jurisdiction, case or circumstance, or of rendering invalid any other provisions of this Agreement to the extent that such other provisions are not themselves actually in conflict with any applicable law. 

  
 Page 6 of 8

 12. COSTS OF ENFORCEMENT: In any dispute arising under or relating to this Agreement, the prevailing
party shall be entitled to recover reasonable attorneys’ and paralegals’ fees and expenses incurred. For this purpose, the term “prevailing party” shall mean the party whose position is substantially sustained in the settlement
or in the final judgment rendered in any litigation. 
 13. HEADINGS: The headings appearing in this Agreement are for convenience and
reference only and shall not be deemed to govern, limit, modify or in any manner affect the scope, meaning or intent of the provisions of this Agreement. 
 14. COUNTERPARTS: This Agreement may be executed in any number of counterparts or by facsimile or Adobe Acrobat PDF file, and by each of the undersigned on separate counterparts, and each such
counterpart shall be deemed to be an original, but all such counterparts put together shall constitute but one and the same Agreement. 
 15.
NOTICE: Any and all notices required, or permitted, to be given under this Agreement will be sufficient if furnished in writing and shall be effective immediately upon personal delivery, or the following day if sent by facsimile transmission
with confirmation of receipt, or two days after being deposited in the U.S. Postal Service, postage prepaid, registered or return receipt requested, or two days after being deposited with a commercial overnight courier (e.g., Federal Express,
DHL, Sonic, etc.), return receipt or confirmation of delivery requested, to the address set forth herein or to such other address of record furnished by either Party to the other in accordance with this Section 15 

[Rest of Page Intentionally Left Blank, Signature Page Follows] 

  
 Page 7 of 8

									
	AGREED TO AND ACCEPTED	 		  		  	
			
	NeoGenomics:	 		  	Medical Group/Physician:
	NEOGENOMICS LABORATORIES, INC.	 		  	ALBITAR ONCOLOGY CONSULTING, LLC
					
	By:	  	 /s/ Douglas M. VanOort
	 		  	By:	  	 /s/ Maher Albitar, M.D.

	Douglas M. VanOort	 		  	Maher Albitar, M.D.
	Chairman and Chief Executive Officer	 		  	President

 The undersigned contracted physician hereby individually joins in this Agreement for the purpose of agreeing to comply
with the provisions of the Agreement. 
  

			
	By:	 	 /s/ Maher Albitar, M.D.

		 	Maher Albitar, M.D.

  
 Page 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]